Smruthi Organics (BOM:540686) has received an "attestation of inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, after the inspection of its active pharmaceutical ingredient (API) manufacturing facility, Unit II in Solapur in Maharashtra, India.
The regulator had inspected the Solar unit from Aug. 27, 2025, to Aug. 29, 2025, and the attestation marks the closure of the EDQM inspection process, according to a BSE filing on Wednesday.
The company said the positive inspection outcome is expected to support its business expansion, improve customer confidence, and create additional opportunities in regulated export markets.
Comments